Regency Capital Management’s DexCom DXCM Stock Holding History

Regency Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	–	–	141
2021 Q1	$0	Buy	+4	New	+$375	﹤0.01%	167

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Regency Capital Management's DXCM Position: Q2 2021 in Review

Regency Capital Management sold out of DexCom (DXCM) in Q2 2021, closing a stake of 4 shares.

Regency Capital Management first reported a position in DXCM in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 726 funds tracked by Wall St. Rank hold DXCM as of Q2 2021.

Regency Capital Management reported no remaining DexCom position as of Q2 2021 after selling out during the quarter.
Regency Capital Management sold 4 DexCom shares in Q2 2021.
Regency Capital Management first reported a position in DexCom in Q1 2021 and held it in 1 quarter.
Regency Capital Management's DexCom position peaked at $0 in Q1 2021.
726 funds tracked by Wall St. Rank held DexCom as of Q2 2021.

Based on Regency Capital Management's 13F filing for Q2 2021, filed 7 Jul 2021.